Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
Semaglutide 在無已知重大精神病理學的體重管理中的精神安全性:STEP 1、2、3 和 5 試驗的事後分析。
JAMA Intern Med 2024-09-03
Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis.
Semaglutide 2.4 毫克在基線時根據抗抑鬱藥使用情況的療效和安全性:事後次級亞組分析。
Obesity (Silver Spring) 2024-02-06
Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.
Liraglutide 3.0 毫克與心理健康:精神症狀是否與治療依循度相關?來自臨床稽核的見解。
Eat Weight Disord 2023-12-01
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
Semaglutide 2.4 毫克用於無糖尿病的超重或肥胖成人減重的功效和安全性:包括為期 2 年的 STEP 5 試驗的更新系統性回顧和荟萃分析。
Diabetes Obes Metab 2024-02-06
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
與semaglutide、liraglutide和tirzepatide相關的精神科不良事件:提交至EudraVigilance數據庫的個別案例安全報告的藥物警戒分析。
Int J Clin Pharm 2024-03-26
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
一次每週 2·4 mg semaglutide 與安慰劑在肥胖及前期糖尿病患者中的療效與安全性 (STEP 10):一項隨機、雙盲、安慰劑對照的多中心第三期試驗。
Lancet Diabetes Endocrinol 2024-08-01
Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
糖尿病和肥胖患者中,胰高血糖素樣肽-1受體激動劑與自殺意念和自我傷害的關聯:一項傾向加權的基於人群的隊列研究。
Diabetologia 2024-08-05
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
來自世界衛生組織數據的 Semaglutide、Liraglutide 與自殺傾向的不成比例分析。
JAMA Netw Open 2024-08-20